Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4333
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$29.11
Market Cap
$3.65B
Change (1 day)
6.51%
Change (1 year)
89.39%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Revenue for Amylyx Pharmaceuticals, Inc. (AMLX)
Revenue in Jun 2026 TTM: 0.00
According to Amylyx Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of $380.79M an increase over the revenue in the year 2022 that was $22.23M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Amylyx Pharmaceuticals, Inc. from 2019 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $87.37M | -77.06% |
| 2023 | $380.79M | 1,612.94% |
| 2022 | $22.23M | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | $650.00K | -54.42% |
| 2019 | $1.43M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
